Direct coupling of the HER4 intracellular domain (4ICD) and STAT5A signaling is required to induce mammary epithelial cell differentiation  by Han, Wen et al.
Biochemistry and Biophysics Reports 7 (2016) 323–327Contents lists available at ScienceDirectBiochemistry and Biophysics Reportshttp://d
2405-58
Abbre
collectio
tein; EG
bovine
heregul
PI3K, ph
verse tr
signal tr
convert
n Corr
E-m
1 Wjournal homepage: www.elsevier.com/locate/bbrepDirect coupling of the HER4 intracellular domain (4ICD) and STAT5A
signaling is required to induce mammary epithelial cell differentiation
Wen Han 1, Mary E. Sfondouris 1, Frank E. Jones n
Department of Cell and Molecular Biology, Tulane University, New Orleans, LA 70118, USAa r t i c l e i n f o
Article history:
Received 24 February 2016
Received in revised form
17 June 2016
Accepted 18 July 2016
Available online 20 July 2016
Keywords:
Mammary epithelial differentiation
EGFR-family
STAT5A
HER4/ERBB4
Gene expression
Transactivationx.doi.org/10.1016/j.bbrep.2016.07.015
08/& 2016 The Authors. Published by Elsevier
viations: 4ICD, HER4 intracellular domain; A
n; EGF, epidermal growth factor; EGFP, enha
FR, epidermal growth factor family; ERα, estro
serum; HEK, human embryonic kidney; HRGα
in beta 1; NLS, nuclear localization signal; PCR
osphoinositide 3-kinase; RIP, regulated intram
anscription; RTK, receptor tyrosine kinase; SH
ansducer and activator of transcription 5A; TA
ing enzyme; WAP, whey acidic protein; YAP,
esponding author.
ail address: fjones3@tulane.edu (F.E. Jones).
en Han and Mary E. Sfondouris contributed ea b s t r a c t
The HER4 receptor tyrosine kinase and STAT5A cooperate to promote mammary luminal progenitor cell
maturation and mammary epithelial cell differentiation. Coupled HER4 and STAT5A signaling is medi-
ated, in part, through association of the HER4 intracellular domain (4ICD) with STAT5A at STAT5A target
gene promoters where 4ICD functions as a STAT5A transcriptional coactivator. Despite an essential role
for coupled 4ICD and STAT5A signaling in mammary gland development, the mechanistic basis of 4ICD
and STAT5A cooperative signaling remains unexplored. Here we show for the ﬁrst time that 4ICD and
STAT5A directly interact through STAT5A recruitment and binding to HER4/4ICD residue Y984. Accord-
ingly, altering the 4ICD Y984 to phenylalanine results in a dramatic reduction of STAT5A and 4ICD-Y984F
interacting complexes coimmunoprecipitated with HER4 or STAT5A speciﬁc antibodies. We further show
that disrupting the 4ICD and STAT5A interaction has an important physiological impact on mammary
epithelial cell differentiation. HC11 mammary epithelial cells with stable expression of 4ICD undergo
differentiation with signiﬁcantly increased expression of the STAT5A target genes and differentiation
markers β-casein and WAP. In contrast, HC11 cells stably expressing 4ICD-Y984F failed to undergo dif-
ferentiation with basal expression levels of β-casein and WAP. Differentiation in this cell system was
induced in the absence of exogenous prolactin indicating that 4ICD activity is sufﬁcient to induce
mammary epithelial cell differentiation. Finally, we show that suppression of STAT5A expression abol-
ishes the ability of 4ICD to induce HC11 differentiation and activate β-casein or WAP expression. Taken
together our results demonstrate for the ﬁrst time that direct coupling of 4ICD and STAT5A is both
necessary and sufﬁcient to drive mammary epithelial differentiation. In conclusion, our ﬁndings that
4ICD and STAT5A directly interact to form a physiologically important transcriptional activation complex,
provide a mechanistic basis for the in vivo observations that HER4/4ICD and STAT5A cooperate to pro-
mote mammary gland progenitor cell maturation and initiate lactation at parturition.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mammary epithelial differentiation requires the complex inter-
play between receptor tyrosine kinases (RTK), cytokine receptors,
and downstream transcription factors. It is well established that
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qually to this work.represents the obligate transcription factor regulating mammary
epithelial differentiation. For example, mammary speciﬁc deletion of
STAT5A results in multiple defects including disengaged secretory
epithelial differentiation, loss of milk-gene expression, and cata-
strophic lactational failure resulting in the death of offspring [1–4].
Signiﬁcantly, recent experimental evidence indicates that STAT5A is
required to establish the luminal progenitor cell population [4,5],
providing a mechanistic basis for the loss of differentiated secretory
epithelium and subsequent failure to lactate observed in STAT5A-null
mice. Ultimately, activation of STAT5A in the differentiating mam-
mary gland is regulated through cooperation between cytokine and
the RTK receptor families. Although cytokine signaling through the
prolactin receptor contributes to STAT5A activity during early preg-
nancy [2,6], the RTK HER4 (also referred to as ERBB4) appears to be
the obligate regulator of STAT5A mediated luminal progenitor func-
tion and differentiation at late pregnancy and parturition [5,6].
HER4 is a unique member of the epidermal growth factor re-
ceptor (EGFR) family. Although, all four members of this RTKnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic of the HER4 intracellular domain (4ICD) residues 673-1308
showing the position of a putative STAT5A binding site, Y984, relative to the HER4
nuclear localization sequence (NLS) [13], and the phosphoinositide 3-kinase (PI3K)
binding site, Y1056, located in the region deleted in the HER4 CYT2 isoform.
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conditions [7], HER4 is the only EGFR-family member that un-
dergoes regulated intramembrane cleavage (RIP) to release an
independently signaling intracellular domain. Accordingly, ligand
activation of HER4 results in tumor necrosis factor-α-converting
enzyme (TACE)-mediated cleavage of the extracellular domain
followed by γ-secretase catalyzed RIP to release the HER4 in-
tracellular domain (4ICD) [8]. Interestingly, nuclear 4ICD functions
as a potent transcriptional coactivator and is recruited to target
gene promoters through association with the transcriptional
coactivator yes-associated protein (YAP) [9] or the DNA-binding
transcription factors estrogen receptor alpha (ERα) [10–12] or
STAT5A [13].
Compelling developmental and experimental evidence in-
dicates that HER4 employs multiple novel activities to regulate
STAT5A induced luminal progenitor cell maturation and mammary
epithelial cell differentiation. The HER4 ligand heregulin alpha
(HRGα), HER4, and STAT5A all have overlapping mammary gland
phenotypes [1,2,4–6,8,14,15]. Accordingly, HRGα stimulation of
HER4 regulates STAT5A activation and subsequent luminal pro-
genitor cell maturation during late pregnancy [5]. Moreover, HRGα
promotes proteolytic processing of HER4 to generate 4ICD, which
functions as a STAT5A nuclear chaperone and transcriptional
coactivator by binding with STAT5A at target gene promoters [13].
STAT5A association with 4ICD and subsequent nuclear co-
translocation is essential for STAT5A mediated gene expression
and mammary epithelial differentiation [6,13,16]. Mechanistically
the association between STAT5A and 4ICD requires an intact
STAT5A Src homology 2 (SH2) domain [13] suggesting that STAT5A
activity requires direct interaction with a speciﬁc phosphorylated
tyrosine within 4ICD. However, the 4ICD residue targeted by this
developmentally and functionally important phosphorylation
event has remained elusive. Here, we demonstrate that phos-
phorylation of 4ICD Y984 is required for 4ICD interaction with
STAT5A and activation of STAT5A target genes during mammary
epithelial differentiation. Our results provide the ﬁrst evidence for
a direct interaction between 4ICD and STAT5A, further establishing
4ICD as a unique and obligate regulator of STAT5A activity during
mammary progenitor cell maturation and mammary epithelial cell
differentiation.Fig. 2. Direct interaction between 4ICD and STAT5A is mediated by HER4 Y984.
HEK 293T cells were transfected with the indicated expression vectors and cell
lysates were prepared at 48 h. post-transfection in EBC buffer. For im-
munoprecipitations, 500 μg of cleared cell lysates were incubated with HER4 or
STAT5A speciﬁc antibodies at 4 °C overnight. Immune complexes were recovered
by adding Protein A sepharose to each immunoprecipitation reaction and in-
cubating for 3 h at 4 °C, and ﬁnally eluted into 60 μl of NuPAGE LDS Sample Buffer
with Reducing Agent. Twenty μl of eluted immunoprecipitation reactions or 20 μg
of EBC lysate (Input) was probed by western blot using the indicated immunoblot
(IB) antibodies.2. Materials and methods
2.1. Expression plasmids
To generate the p4ICD expression vector, the HER4 intracellular
domain (4ICD) (residues 673-1308), was subcloned into pEGFP-N3
(Clontech) with the N-terminal EGFP removed. The Y984F mutation
was produced by PCR-assisted site-directed mutagenesis of p4ICD
using the primer 5′-GGCTCGAGACCCTCAAAGATTCCTAGTTATTCAGGG-
3′ (altered base underlined) and the QuickChange II XL Site-Directed
Mutagenesis Kit (Agilent). The full length mouse STAT5A expression
vector pEFneo-STAT5A has been described previously [14].
2.2. Cell lines
All cell lines were obtained from American Type Culture Col-
lection (ATCC). The human embryonic kidney cell line HEK 293T
was cultured in DMEM (Gibco) supplemented with 10% fetal bo-
vine serum (FBS) and 2 mM L-glutamine. HC11 mouse mammary
epithelial cells were cultured in RPMI 1640 (Gibco) supplemented
with 10% FBS, 10 ng/ml epidermal growth factor (EGF) (Invitrogen),
5 mg/ml insulin (Sigma-Aldrich), and 1 mg/ml hydrocortisone (Sig-
ma-Aldrich). For stable expression of 4ICD or 4ICD-Y984F, HC11
cells were transfected with p4ICD, p4ICD-Y984F or the emptyvector using Fugene6 (Roche) and selected with G418 to generate
the pooled cell lines HC11/4ICD, HC11/4ICD-Y984F, and HC11/
vector, respectively. Where indicated, differentiation of HC11
stable cell lines was induced by culturing conﬂuent cells in FBS
and EGF free culture media.
2.3. Immunoprecipitation and western blot analysis
Co-immunoprecipitation of STAT5A and 4ICD or 4ICD-Y984F was
performed exactly as described previously [13,17] using HEK 293T
cells were transfected with pEFneo-STAT5A, p4ICD or p4ICD-Y984F
using Lipofectamine with Plus Reagent (Invitrogen). At 2 days post-
transfection, cell lysates were prepared in EBC buffer (50 mM Tris, pH
7.5, 50 mM Tris, pH 7.5, 0.5% NP-40, with 1 mM phenylmethylsulfo-
nyl ﬂuoride) and 500 μg of lysate was immunoprecipitated overnight
Fig. 3. 4ICD induced mammary epithelial cell differentiation requires an intact Y984. (A) HER4/4ICD western blot analysis of HC11 mammary epithelial stable cell lines HC11/
vector, HC11/4ICD, and HC11/4ICD-Y984F demonstrating equivalent levels of 4ICD and 4ICD-Y984F expression. Western blot of α-tubulin is included as a loading control. Each
indicated HC11 stable cell line was induced to undergo differentiation in the absence of exogenous prolactin by serum starvation for two days and expression, normalized to
β-actin, of the differentiation markers (B) β-casein and (C) WAP relative to HC11/vector control was determined by quantitative RT-PCR. Each quantitative RT-PCR sample was
prepared in triplicate and the data represent the mean and standard error (SE) of at least three independent experiments and RNA extractions. Statistically signiﬁcant
differences between data sets were determined using one-way ANOVA with Bonferroni post-hoc test. Single or double asterisks indicates po0.03 or p¼0.003, respectively.
Fig. 4. STAT5 expression is required for 4ICD induced mammary epithelial cell differentiation. (A) STAT5 western blot analysis of the HC11 mammary epithelial stable cell
lines HC11/vector and HC11/4ICD transfected with scramble siRNA control or STAT5 siRNA after cells were induced to undergo differentiation in the absence of exogenous
prolactin, by serum starvation for two days. Western blot of α-tubulin is included as a loading control. Superﬂuous gel lanes between 4ICD and 4ICD STAT5 KD were removed
to condense the ﬁgure panel. Expression, normalized to β-actin, of the differentiation markers (B) β-casein and (C) WAP relative to HC11/vector control treated with scramble
siRNA was determined by quantitative RT-PCR. Each quantitative RT-PCR sample was prepared in triplicate and the data represent the mean and standard error (SE) of at
least three independent experiments and RNA extractions. Statistically signiﬁcant differences between data sets were determined using one-way ANOVA with Bonferroni
post-hoc test. Asterisks indicate po0.05.
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STAT5 (Santa Cruz; sc-835). Immune complexes were collected by
incubating with Protein A sepharose (Roche) at 4 °C for 3 h. and
eluted by boiling in 60 μl of NuPAGE LDS Sample Buffer (4X) (Life
Technologies) containing NuPAGE Sample Reducing Agent (10X) (Life
Technologies). Twenty μl of each immunoprecipitate was loaded in
each lane of a NuPAGE 4–12% Bis–Tris Gel (Life Technologies). Total
cell lysates were collected using RIPA Buffer (10 mM NaPO4, pH 7.2,
150 mMNaCl, 1 mM EDTA, 0.1% SDS, 1% Na-deoxycholate, 1% Nonidet
P40) containing Complete EDTA-free Protease Inhibitor Cocktail
(Roche) and PhosSTOP phosphatase inhibitor (Roche) and western
blot analysis was performed exactly as described previously [18]
using the primary antibodies directed against HER4 (Abcam; E200),
Stat5 (Santa Cruz; sc-835), and α-tubulin (Upstate Biotechnology;
05829).
2.4. Quantitative RT-PCR
Triplicate total RNA samples were isolated from stable HC11 cell
lines induced to undergo differentiation and quantitative RT-PCR was
performed exactly as described elsewhere [10] using the following
PCR primer pairs to amplify β-actin 5′-CGACTGTGTCATGACATGTAC
and 5′-TTGAAAGCATTATGTTCTCTCTGG, β-casein 5′-CGACTGTGTCAT-
GACATGTAC and 5′-TTGAAAGCATTATGTTCTCTCTGG or whey acidicprotein (WAP) 5′-CATCCTCGCCTGCCTTGTGGC and 5′-CCATGA-
GATTCACCTTCTGAAG. The Ct analysis for each reaction was per-
formed using the supplied 7500 Software v2.0.5 (Applied Biosys-
tems) and gene expression levels were normalized to β-actin using
the ΔΔCt method.
2.5. STAT5A knockdown
To suppress expression of endogenous STAT5, the HC11 stable
cell lines HC11/vector and HC11/4ICD were grown to conﬂuency
and transfected with siRNA targeting STAT5 (Sigma; WD03944063)
or scramble siRNA (Sigma; WD03148542) in FBS- and EGF-free
RPMI 1640 using Lipofectamine RNAiMAX Reagent (Invitrogen)
according to the manufacturer's instructions.3. Results and discussion
3.1. HER4 Y984 mediates the interaction between 4ICD and STAT5A
Our previously published data suggests that 4ICD directly in-
teracts with STAT5A [8,13,17]. Furthermore, this interaction requires
an intact STAT5A Src homology 2 (SH2) domain [13], which med-
iates STAT5A interaction with phosphorylated tyrosine residues.
W. Han et al. / Biochemistry and Biophysics Reports 7 (2016) 323–327326Although HER4 harbors a total of 27 intracellular tyrosine residues
one report indicates that only 19 undergo phosphorylation in re-
sponse to the HER4 ligand HRGβ1. However, STAT5A was not in-
cluded in the subsequent unbiased phospho-peptide screen de-
signed to identify SH2-mediated HER4 interacting partners [19].
This limitation precluded identiﬁcation of potential HER4 phos-
photyrosines required to recruit STAT5A. A similar unbiased inter-
actome of all 27 HER4 cytosolic tyrosines revealed STAT5A inter-
action with a phosphotyrosine representing Y984 positioned within
the ﬁnal carboxyl residues of the intrinsic tyrosine kinase domain
[20] (Fig. 1). However, the synthetic peptide-peptide interaction was
not conﬁrmed experimentally and the physiological relevance of a
HER4/STAT5A interaction remains to be established.
To conﬁrm that HER4 Y984 mediates an interaction between
4ICD and STAT5A we used site-directed mutagenesis of 4ICD to
replace Y984 with phenylalanine (Y984F). Both ectopically ex-
pressed 4ICD and 4ICD Y984F displayed relatively low but
equivalent levels of autophosphorylation (Supplementary Fig. S1)
indicating that the Y984F alteration failed to dramatically impact
the 4ICD intrinsic tyrosine kinase activity. Using a coimmunopre-
cipitation assay of HEK 293T transiently transfected with STAT5A
and 4ICD or 4ICD-Y984F, we show that, consistent with previously
published results [13,17], both the HER4 and STAT5A speciﬁc an-
tibodies coimmunoprecipitate the HER4 and STAT5A interacting
complex (Fig. 2; lane 5). Signiﬁcantly, altering the 4ICD Y984 to
phenylalanine results in a dramatic reduction of STAT5A and 4ICD-
Y984F interacting complexes coimmunoprecipitated with HER4 or
STAT5A speciﬁc antibodies (Fig. 2; lane 6). These results indicate
that Y984 is the major HER4 phosphotyrosine required to mediate
a direct interaction between 4ICD and STAT5A.
3.2. Mammalian epithelial cell differentiation requires an intact 4ICD
Y984
Previous reports have shown that expression of 4ICD is sufﬁ-
cient to induce mammary epithelial cell differentiation in both
in vivo and in vitro experimental systems [21,22]. The mouse
mammary epithelial HC11 cell line is a commonly employed model
of prolactin-induced mammary differentiation. These cells also
undergo differentiation, in the absence of prolactin signaling, in
response to 4ICD expression and serum starvation. To determine
the physiological role for 4ICD Y984 during mammary epithelial
cell differentiation, we induced differentiation of HC11 cells stably
transfected with 4ICD or 4ICD-Y984F. The two pooled HC11/4ICD
and HC11/4ICD-Y984F stable cell lines displayed equivalent levels
of ectopic 4ICD expression (Fig. 3A). Consistent with a role for 4ICD
in mammary epithelial cell differentiation, ectopic expression of
4ICD resulted in a signiﬁcant increase in HC11 expression of the
differentiation markers and STAT5A target genes β-casein (Fig. 3B)
and WAP (Fig. 3C). In contrast, ectopic expression of 4ICD-Y984F
failed to signiﬁcantly increase HC11 expression of β-casein
(Fig. 3B) or WAP (Fig. 3C). These results indicate that an intact 4ICD
Y984 is required to induce mammary epithelial differentiation and
suggests that phosphorylated Y984 recruits STAT5A to drive
mammary differentiation.
3.3. 4ICD-induced mammary epithelial cell differentiation requires
STAT5A expression
Activation of STAT5A during 4ICD-induced HC11 cell differ-
entiation suggests that STAT5A is the downstream effector of 4ICD
activity in this experimental system [21]. Our ﬁndings that ablat-
ing 4ICD Y984, which is required for 4ICD to recruit STAT5A,
abolishes the ability of 4ICD to induce HC11 differentiation, further
substantiates an obligate role for STAT5A in 4ICD-induced mam-
mary epithelial cell differentiation. To conﬁrm a role for STAT5A in4ICD-induced HC11 differentiation, we determined the impact of
siRNA-mediated suppression of STAT5A on the differentiation of
HC11/4ICD cells. Consistent with previous results (Fig. 3), differ-
entiation of HC11/4ICD cells transfected with non-speciﬁc siRNA
(Fig. 4A) resulted in a signiﬁcant increase in expression the
β-casein (Fig. 4B) and WAP (Fig. 4C) differentiation genes when
compared to control HC11/vector cells. We successfully used siRNA
to suppress STAT5A expression in the HC11/4ICD cells stimulated
to undergo differentiation (Fig. 4A). However, in the absence of
STAT5A the HC11/4ICD cells failed to induce signiﬁcant levels of β-
casein (Fig. 4B) or WAP (Fig. 4C) expression demonstrating for the
ﬁrst time that STAT5A is required for 4ICD induced differentiation
of HC11 cells. Prolactin stimulation of β-casein and WAP was also
suppressed, further conﬁrming functional knockdown of STAT5 in
the HC11/4ICD cells (Supplementary Fig. S2).
In conclusion, compelling in vivo and in vitro evidence suggests
that 4ICD and STAT5A cooperate to drive mammary epithelial cell
differentiation; however, experiments demonstrating direct cou-
pling of these two signaling pathways have remained elusive. Here
we show for the ﬁrst time that STAT5A directly interacts with 4ICD
and this interaction occurs through STAT5A binding to Y984 of
4ICD. We further demonstrate that the 4ICD and STAT5A interac-
tion is physiologically relevant and required to drive mammary
epithelial cell differentiation. Taken together our ﬁndings are sig-
niﬁcant because they indicate that 4ICD and STAT5A can induce
mammary epithelial cell differentiation in the absence of prolactin
signaling. Furthermore, our ﬁndings that 4ICD and STAT5A directly
interact to form a physiologically important functional complex
provide a mechanistic basis for the observations that HER4/4ICD
and STAT5A cooperate to promote mammary gland progenitor cell
maturation and initiate lactation at parturition.Acknowledgments
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